Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe Guidance for Industry: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
December 14, 2022
December 14, 2022
2cb79d52-2f8b-43f0-b3e6-438ef7b8a9d1
Related Documents
Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics: Guidance for Industry
Guidance DocumentDecember 19, 2018Center for Drug Evaluation and Research
Post-Complete Response Letter Clarification Teleconferences Between FDA and ANDA Applicants Under GDUFA Guidance for Industry
Guidance DocumentOctober 5, 2022Center for Drug Evaluation and Research
Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments: Guidance for Industry
Guidance DocumentOctober 5, 2022Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox